Paper6147754
Comparative biochemical properties of normal and activated human ras p21 protein.
McGrath JP and 3 others. Nature, 1984. Cited by 648 papers, by iCite.
Cite this record
ConductScience Library. Comparative biochemical properties of normal and activated human ras p21 protein. Papers, record 6147754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6147754
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA | Major topic |
| Neoplasm Proteins | Major topic |
| Oncogenes | Major topic |
| Cloning, Molecular | |
| DNA Restriction Enzymes | |
| Escherichia coli | |
| GTP Phosphohydrolases | |
| Guanosine Triphosphate | |
| Humans | |
| Mutation | |
| Oncogene Protein p21(ras) | |
| Phosphorylation | |
| Protein Binding | |
| Proto-Oncogene Proteins p21(ras) | |
| RNA, Messenger | |
| Substrate Specificity |
Source PubMed
Cited by207
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 648 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42270775 | Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors. | Oncogene | 2026 | https://conductscience.org/library/papers/42270775 | PubMed |
| 39638567 | "Undruggable KRAS": druggable after all. | Genes Dev | 2025 | https://conductscience.org/library/papers/39638567 | PubMed |
| 38888731 | RAS-Mutant Follicular Thyroid Tumors: A Continuous Challenge for Pathologists. | Endocr Pathol | 2024 | https://conductscience.org/library/papers/38888731 | PubMed |
| 38882681 | Isomer-sourced structure iteration methods for in silico development of inhibitors: Inducing GTP-bound NRAS-Q61 oncogenic mutations to an "off-like" state. | Comput Struct Biotechnol J | 2024 | https://conductscience.org/library/papers/38882681 | PubMed |
| 38570454 | Measurement of KRAS-GTPase Activity. | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/38570454 | PubMed |
| 37833074 | Structural insights into the complex of oncogenic KRas4BG12V and Rgl2, a RalA/B activator. | Life Sci Alliance | 2024 | https://conductscience.org/library/papers/37833074 | PubMed |
| 37676964 | Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. | Science | 2023 | https://conductscience.org/library/papers/37676964 | PubMed |
| 35966590 | Conquering oncogenic KRAS and its bypass mechanisms. | Theranostics | 2022 | https://conductscience.org/library/papers/35966590 | PubMed |
| 35582595 | Targeting the "undruggable" RAS - new strategies - new hope? | Cancer Drug Resist | 2019 | https://conductscience.org/library/papers/35582595 | PubMed |
| 35373279 | Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. | Cancer Discov | 2022 | https://conductscience.org/library/papers/35373279 | PubMed |
| 35098800 | KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. | Ther Adv Respir Dis | 2022 | https://conductscience.org/library/papers/35098800 | PubMed |
| 35070984 | Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. | Front Oncol | 2021 | https://conductscience.org/library/papers/35070984 | PubMed |
| 34220225 | Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations. | Saudi J Biol Sci | 2021 | https://conductscience.org/library/papers/34220225 | PubMed |
| 32797215 | RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. | Biochem J | 2020 | https://conductscience.org/library/papers/32797215 | PubMed |
| 32689909 | Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. | Thyroid | 2021 | https://conductscience.org/library/papers/32689909 | PubMed |
| 30224050 | Water Distribution within Wild-Type NRas Protein and Q61 Mutants during Unrestrained QM/MM Dynamics. | Biophys J | 2018 | https://conductscience.org/library/papers/30224050 | PubMed |
| 28448128 | Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). | J Am Chem Soc | 2017 | https://conductscience.org/library/papers/28448128 | PubMed |
| 27412009 | Pathogenetics of the RASopathies. | Hum Mol Genet | 2016 | https://conductscience.org/library/papers/27412009 | PubMed |
| 26765565 | Mapping the functional versatility and fragility of Ras GTPase signaling circuits through in vitro network reconstitution. | Elife | 2016 | https://conductscience.org/library/papers/26765565 | PubMed |
| 26344768 | Cross-Talk between Carbon Metabolism and the DNA Damage Response in S. cerevisiae. | Cell Rep | 2015 | https://conductscience.org/library/papers/26344768 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| H3P16 | 644914 | PubTator's text mining | https://conductscience.org/library/genes/644914 | NCBI Gene |
| HRAS | 3265 | PubTator's text mining | https://conductscience.org/library/genes/3265 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6147754
GET https://conductscience.org/api/papers/v1/6147754/cited_by?page=2